For black worshipers in New Orleans, religious beliefs can affect health.

Published Date: 02 Mar 2023

Members of the New Orleans Black Church who believe religion plays an important role in health may eat more fruits and vegetables, be physically active, and be more likely to ask more health questions. .

Read Full News

Latest News

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Todays Updates

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Todays Updates

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Latest News

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

News All Time

Where Does Ameluz PDT Fit Alongside Mohs Surgery? Neal Bhatia, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

7 Dermatology Headlines You Missed in September 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

What the FDA's Approval of Ameluz PDT Means for Skin Cancer Neal Bhatia, MD

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know Victoria Johnson

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

FDA News Recap: Novel Drug Approvals in Q3 2026

NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates

NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

Nail Detachment 4 Times More Common With GLP-1 Use

Nail Detachment 4 Times More Common With GLP-1 Use

Key Lessons in Leadership as a Clinician, With Kristina Duffin, MD Kristina Duffin, MD

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU Tim Smith

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Climate Change Tied to Skin Disease Worsening in 42% of Countries

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis Tim Smith

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

Recommended News For You

CAR T cells improve patients' quality of life: a study

The Benefits of Exercise for Substance Use Disorders.

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

Breast Cancer Incidence Rises in Asian American Women

Prostate cancer screening program beneficial in top decile of polygenic risk score

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

Recommended Articles For You

Hematology Services in Remote Regions: Challenges, Innovations, and Clinical Implications 

Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions 

Molecular Matching for Precision Cancer Therapy 

CAR-T Therapy in Blood Cancers: Mechanisms, Efficacy, and Clinical Integration 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

2.

Dissociative identity disorder: method or fact?

3.

New Gene Therapy Nears EU Nod for Bladder Cancer

4.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

5.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

1.

Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide 

2.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

3.

Digital Cancer Caregiver Coordination Platforms: Advances, Clinical Impact, and Future Directions

4.

Community Strategies for Improving Cancer Prevention Literacy

5.

Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Thromboprophylaxis In Medical Settings

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

5.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot